Depression Screening Market, Mental Health Market
Depression Screening Market, Mental Health Market

Depression and mental health are the significant medical problems over the globe. Expanding pervasiveness of different mental issue, social and ecological changes, and changing way of life are real drivers for the market development. Rising financing for R&D and clinical trials are additionally driving the development for Depression Screening/Mental Health Market. Expanding attention to disarranges and medicines, quick selection of new treatments and medications, and mechanical progression are key drivers for the market. The Global Depression Screening/Mental Health market is growing at the CAGR of ~4.5% during the forecast period and expected to reach US$ 11245.6 million by 2023.

Competitive Landscapes:

Some of the key players in this market are: Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan),  Pfizer Inc. (US), and others.

Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/3806 .

Segments:

Global depression screening/mental health market has been segmented on the basis of disorder which comprises of anxiety, mood disorders, depression, bipolar behavior, psychosis, eating disorders, impulse control & addiction disorders, personality disorders, stress response syndromes, dissociative disorder, somatic symptom disorder, factitious disorder, and others. Anxiety is further sub-segmented into Generalized Anxiety Disorder (GAD), panic disorder, phobias, Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD). Mood disorder is further sub-segmented into dysthymia, substance-induced mood disorder, major depression, and others. Depression is further sub-segmented into atypical depression, chronic depression, melancholic depression, catatonic depression, Seasonal affective disorder (SAD), and others. Bipolar disorder is further sub-segmented into bipolar I disorder, bipolar II disorder, cyclothymic disorder, and others. Psychotic disorder is further sub-segmented into schizophrenia, delusional disorder, and others. Eating disorder is further sub-segmented into anorexia nervosa, binge eating disorder, bulimia nervosa, and others. Impulse control and addiction disorder is further sub-segmented into intermittent explosive disorder, pyromania, kleptomania, and others. Personality disorders include various traits such as emotional & impulsive, suspicious, anxious, and others. Dissociative disorder is sub-segmented into dissociative amnesia, dissociative identity disorder, depersonalization- derealization disorder, and others. Somatic symptom disorder somatization disorder, conversion disorder, hypochondriasis, factitious disorder, body dysmorphic disorder, and others. Factitious disorder is further sub-segmented into factitious disorder with mostly psychological symptoms, factitious disorder with mostly physical symptoms, factitious disorder with both psychological and physical symptoms, and others.

On the basis of diagnosis, the market has been segmented into psychological test, Lab tests, Depression Screening Tests and others. Psychological test is further sub-segmented into intelligence tests, attitude tests, personality tests, achievement tests, and others. Lab tests sub-segmented into blood tests, CT scan or MRI of the brain, Electroencephalogram (EEG), Electrocardiogram (ECG).  Depression Screening Tests includes Patient Health Questionnaire-10 (PHQ-10), Beck Depression Inventory (BDI), Zung Self-Rating Depression Scale, Center for Epidemiologic Studies-Depression Scale (CES-D), and Hamilton Rating Scale for Depression (HRSD).

Order Single User License Copy of 78 Premium Pages is Available @ https://www.marketresearchfuture.com/order_form.pdf?report_id=3806 .

On the basis of treatment, the market has been segmented into medication, psychotherapy, brain-stimulation treatments, hospitalization, substance abuse treatment, and others. Medication includes anti-anxiety medications, antidepressants, antipsychotic medications, mood-stabilizing medications, opioid antagonists, atypical neuroleptics, glutamatergic agents, and others. Psychotherapy is further sub-segmented into cognitive and behavioural therapies, humanistic therapies, psychoanalytical and psychodynamic therapies, and others. Brain-stimulation treatments includes repetitive Transcranial Magnetic Stimulation (rTMS), Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and others.

On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

Brief TOC

  1.  Report Prologue

    2.    Introduction

    2.1    Definition
    2.2    Scope of the Study

    2.2.1    Research Objective
    2.2.2    Assumptions
    2.2.3    Limitations

    2.3    Market Structure
    2.4.    Market Segmentation

    3.    Research Methodology

    3.1    Research Process
    3.2    Primary Research
    3.3    Secondary Research
    3.4    Market Size Estimation
    3.5    Forecast Model

    4.    Market Dynamics

    4.1    Drivers
    4.2    Restraints
    4.3    Opportunities
    4.4    Mega Trends
    4.5    Macroeconomic Indicators

    5.    Market Factor analysis

….Continued

Ask to Expert @ https://www.marketresearchfuture.com/enquiry/3806 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand,

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here